The Pharmacyclics Pipeline
- About Us
- Pipeline
- Clinical Trials
- BTK Inhibitors - References
B-cell Lymphoma - PCYC 1102 CA BTK Inhibitor
CLL/SLL - PCYC 1103 CA BTK Inhibitor
B-cell Lymphoma and CLL - PCYC 1104 CA BTK Inhibitor
Relapsed or Refractory Mantle cell Lymphoma - PCYC 1106 CA BTK Inhibitor
Relapsed or Refractory Non-Hodgkin’s DLBCL Lymphoma - PCYC 1108 CA BTK Inhibitor
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - PCYC 1109 CA BTK Inhibitor
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia - PCYC 1111 CA BTK Inhibitor
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma - PCYC 1001 Factor VIIa Inhibitor Pancreatic Cancer
- PCYC 0403 HDAC Inhibitor
B-cell Lymphoma - PCYC 0405 HDAC Inhibitor
Long-Term Safety Trial in B-cell Lymphoma - RTOG 0513 MGd
Glioblastoma - Glossary of Terms
- BTK Inhibitors - References
- Investors & Media
- Careers
- Contact Us
